Oral News and Research

RSS

Oral nutritional supplements linked with decreased probability of 30-day hospital readmission

In the U.S., one in five Medicare patients is readmitted to a hospital each year at an estimated cost of $17.5 billion annually.i To reduce this impact, the Affordable Care Act (ACA) has introduced hospital penalties based on readmissions conditions that commonly affect patients aged 65 and older - including acute myocardial infarction, congestive heart failure and pneumonia.

19 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

Celmatix presents six research findings at ASRM's annual meeting

Celmatix, a biotechnology company focused on helping physicians guide patients to treatments that maximize their personal reproductive potential, announced today six research presentations at the annual meeting of the American Society for Reproductive Medicine, being held October 12-17 in Boston.

17 Oct 2013

Overutilization of radioactive iodine to treat PTC leads to worse access to health care

The American Thyroid Association (ATA) recommends against the routine use of radioactive iodine after surgery to remove the thyroid in patients with low-risk papillary thyroid cancer (PTC).

17 Oct 2013

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

A new study suggests a growing number of U.S. adolescents lack antibodies that may help protect them later in life against an increasingly important cause of genital herpes. Published in The Journal of Infectious Diseases and available online, the findings show that fewer of today's teens have been exposed in their childhood to herpes simplex virus type 1 (HSV-1), a common cause of cold sores, than U.S. adolescents in previous years.

17 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013

Evidence less consistent for high blood sugar, insulin treatment and oral agents

Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University was senior author of a consensus statement from the American Association of Clinical Endocrinologists on diabetes and cancer, which was just published in Endocrinology Practice.

16 Oct 2013

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Today, the Population Council presented findings from a Phase 3 clinical trial that was designed to demonstrate the safety, efficacy, and acceptability of the Council's investigational one-year contraceptive vaginal ring (CVR).

16 Oct 2013

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces positive results from its Phase II study of APD515 for the treatment of xerostomia (dry mouth) in advanced cancer patients.

15 Oct 2013

Colorcon, Evonik partner to market and support Acryl-EZE aqueous acrylic enteric system

Colorcon and Evonik have announced the signing of a cooperation agreement for the market promotion and technical support of Acryl-EZE, aqueous acrylic enteric system.

15 Oct 2013

Drug treatment ineffective for acute bronchitis

A study published in the BMJ indicates that neither oral antibiotics nor nonsteroidal anti-inflammatory drugs are more effective than placebo for the treatment of acute bronchitis.

14 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Study examines how real people evaluate the behavior of themselves, friends and strangers

There is no such thing as objectivity when it comes to your friends: According to a new study, people evaluate their friends' behavior more positively than do strangers, regardless of actual performance on a series of tasks. Researchers say that we should then think twice before allowing people who know each other to be in positions to judge each other - from job interviews to legal settings.

13 Oct 2013

New study illustrates impact of oral nutrition supplement use in pediatric hospitalized patients

A new study has found that the use of oral nutritional supplements provided to pediatric patients during hospitalization was associated with a decrease in length of stay of 14.8 percent and a decrease in hospital stay costs of $1,768 per patient.

12 Oct 2013

Scientists decode key molecular gateway for toxin that causes botulism

U.S. and German scientists have decoded a key molecular gateway for the toxin that causes botulism, pointing the way to treatments that can keep the food-borne poison out of the bloodstream.

12 Oct 2013

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

...

11 Oct 2013

Auxilium Licenses Stendra From Vivus For Up To $300M

...

11 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Evidence shows vaccination pilot campaigns highly successful during 2010 cholera epidemic

The deadly cholera epidemic that rocked earthquake-shattered Haiti in 2010, claiming 8,000 lives and counting, has rallied the public health community to seek water and sewer improvements that, combined with vaccination, could prevent some 89,000 future cholera infections.

11 Oct 2013

Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC

C hemoradiation is superior to chemotherapy alone with respect to both survival and quality of life in patients with inoperable non-small-cell lung cancer, a phase III trial has found.

10 Oct 2013

Oral News and Research

Oral nutritional supplements linked with decreased probability of 30-day hospital readmission

Recombinant hormone could REPLACE calcium supplements

Celmatix presents six research findings at ASRM's annual meeting

Overutilization of radioactive iodine to treat PTC leads to worse access to health care

Most U.S. adolescents lack antibodies that may help protect against genital herpes, says study

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Evidence less consistent for high blood sugar, insulin treatment and oral agents

Results of Phase 3 clinical trial of contraceptive vaginal ring presented by Population Council

Acacia Pharma reports positive results from APD515 Phase II study for treatment of xerostomia

Colorcon, Evonik partner to market and support Acryl-EZE aqueous acrylic enteric system

Drug treatment ineffective for acute bronchitis

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Study examines how real people evaluate the behavior of themselves, friends and strangers

New study illustrates impact of oral nutrition supplement use in pediatric hospitalized patients

Scientists decode key molecular gateway for toxin that causes botulism

Astrazeneca, Janssen To Promote Novel Prostate Cancer Treatment In Japan

Auxilium Licenses Stendra From Vivus For Up To $300M

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Evidence shows vaccination pilot campaigns highly successful during 2010 cholera epidemic

Palliative chemoradiation boosts survival, QoL in poor-prognosis NSCLC

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News